South Africa's 2026 Medicine Import Rule Correction: What Changed—and What Did Not

A two-document timeline

The sequence matters. The 7 August Gazette is the formal published amendment. SAHPRA's 12 August communication is an official statement of the regulator's intended correction, but it says SAHPRA has requested repeal and replacement. It does not itself reproduce a replacement regulation. That gap is why a time-stamped source check is more responsible than a categorical claim that the permit clause either unquestionably applies or has already disappeared.^1,2

What the 7 August Gazette changed

1. New definitions for substandard and falsified medicine

The amendment deletes the former regulatory definition of “counterfeit medicine”. It defines a substandard medicine as one that fails to meet its quality standards or specifications, or both. It defines a falsified medicine as one whose identity, composition or source is deliberately or fraudulently misrepresented.¹

These are not interchangeable labels. “Substandard” is about a failure against quality standards or specifications. “Falsified” adds deliberate or fraudulent misrepresentation. A quality failure does not automatically prove fraud, and suspicious packaging alone does not establish the composition of what is inside. SAHPRA's rapid-alert process describes investigation, testing and regulatory action as evidence develops.⁵

2. Expanded ports of entry

For imports by air or sea, the amended Regulation 6 lists Cape Town International Airport or Cape Town harbour; Chief Dawid Stuurman International Airport, Port Elizabeth harbour or Ngqura harbour; King Shaka International Airport or Durban harbour; and O.R. Tambo International Airport.¹

It also provides for specified land-border entry through Beit Bridge, Vioolsdrift, a Botswana border post, Maseru Bridge, Lebombo and Oshoek, in a manner determined by SAHPRA and subject to notification and approval of the intended importation. The Gazette's Botswana entry is incomplete—it says only “border post”—so it should not be converted into a guessed location in operational guidance.¹

3. The permit clause SAHPRA asked to correct

The 7 August text added Regulation 6(4), stating that no person may import or export scheduled substances, medicines or health products unless a permit has been issued by the CEO or Authority in the prescribed manner and subject to determined conditions.¹ SAHPRA then said this aspect should first have been published for public comment, requested its repeal and replacement, and said proposed permit requirements would be consulted on later.²

What this means for peptide claims

The import-rule correction does not reverse SAHPRA's 2026 public warning on unregistered peptide products. That warning identifies online platforms, social media, gyms, wellness centres and informal suppliers as channels of concern, and names examples including BPC-157, TB-500, Melanotan II, CJC-1295, ipamorelin, PT-141, AOD-9604, Selank and Semax.⁶

SAHPRA's stated position is that a product intended to treat, prevent or alter bodily functions must be registered before sale in South Africa. A “research use only” label does not establish that a product is a registered medicine, approved for self-administration, lawfully imported for therapeutic sale, or supported by human clinical evidence.⁶

A practical verification workflow

1. Identify the exact product—not only the peptide or active-ingredient name. Record the finished-product name, presentation, manufacturer, supplier, batch and expiry.
2. Check the exact finished product in SAHPRA's registered-health-products resources. Do not assume that registration of one brand covers every powder, vial, pen, compounded preparation or combination containing the same molecule.⁷
3. If an unregistered medicine is said to be available through Section 21, ask the responsible healthcare professional about the specific authorisation and conditions. Section 21 is controlled access, not general product registration.⁸
4. For commercial supply-chain questions, verify the establishment and licence scope through SAHPRA's current licensing resources. SAHPRA's licensing guideline is directed to applicants seeking to manufacture, import or export medicines or scheduled substances.^3,9
5. Check current rapid alerts and recalls. A registration search does not replace a batch-specific recall check.^5,10
6. Keep any packaging, receipt, batch information, analytical report and correspondence if a product appears suspicious. These details help a regulator or laboratory investigate.
7. Report suspected quality, safety, efficacy or advertising problems through SAHPRA's complaint channels; report suspected adverse reactions through Med Safety. Seek urgent clinical care first for severe symptoms.^11,12

What this article does—and does not—establish

• It confirms what Government Notice 7780 says on its face as published on 7 August 2026.¹
• It confirms that SAHPRA announced a requested correction on 12 August 2026 and described the consultation it expects for future permit requirements.²
• It does not certify the legal status of a particular shipment, importer, peptide, medicine or seller.
• It does not treat an unregistered product as falsified without evidence of deliberate or fraudulent misrepresentation.
• It does not turn preclinical peptide research into a human treatment recommendation.